Sunshine Biopharma Receives Canadian Approval to Launch Generic Hypertension Drug Enalapril
The drug is a generic version of the well-known brand Vasotec and will be available in 2.5mg, 5mg, 10mg, and 20mg tablet strengths. Sunshine Biopharma plans to distribute it in Canada through its wholly-owned subsidiary, Nora Pharma Inc., with the first products expected to arrive at retail pharmacies by the end of 2026.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
24H Trending
-
1
AFIN Coin: Exploring Its Connection to Cryptocurrency and Sustainable Development, and Its Future Prospects
-
2
Iraq's state tanker company arranges VLCC to transport 2 million barrels of crude beyond Strait of Hormuz, shifting oil strategy to offer oil outside Persian Gulf
-
3
a16z Podcast: AI-Native Startups Are Challenging Traditional Giants in Enterprise Software Through "End-to-End Processes"
-
4
DVI Coin: An Analysis of Dvision Network's Virtual Reality Metaverse Token
-
5
Stellar (XLM) accounts for 37% of the global RWA tokenization market, with daily inflows of $36.4 million.
-
6
Al Jazeera: Russia faces €18.7 billion nuclear plant decommissioning funding gap
-
7
Bank of America warns: The AI narrative is acting as a "buffer" against macro risks, and its failure could trigger a market-wide crisis.
-
8
Chinese AI micro-drama producers face audience fatigue, NetEase uses AI to recreate Joey Wong's classic roles.
-
9
EPFR data shows: Bonds saw net inflows of $18.8 billion, with long-term bond inflows reaching their largest since May 2025.
-
10
Needham: Meta Valuation Rises 35% After Including $628 Billion in Off-Balance Sheet Liabilities
Markets Today
Recommended Reading




